2023
Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearance
2022
Patient perspectives on the lived experience of granuloma annulare
Clark A, Murphy M, King B, Cohen J, Rosenbach M, Barbieri J, Damsky W. Patient perspectives on the lived experience of granuloma annulare. British Journal Of Dermatology 2022, 188: 134-136. PMID: 36689498, DOI: 10.1093/bjd/ljac004.Peer-Reviewed Original ResearchAntibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris
Swallow MA, Fan R, Cohen JM, Bunick CG. Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris. Antibiotics 2022, 11: 1032. PMID: 36009899, PMCID: PMC9405006, DOI: 10.3390/antibiotics11081032.Peer-Reviewed Original ResearchAcne vulgarisSevere acne vulgarisAntibiotic resistancePotential side effectsOral tetracyclineGut dysbiosisPatients 9Gastrointestinal upsetRisk of resistanceSide effectsDrug AdministrationTetracycline treatmentSarecyclineTetracycline usageAcneTreatmentTetracyclineAntibiotic resistance riskPathogenic bacteriumRiskVulgarisDizzinessVertigoDysbiosisMinocycline
2020
Early Adoption of Dupilumab in the Medicare Population in 2017.
Cheraghlou S, Cohen JM. Early Adoption of Dupilumab in the Medicare Population in 2017. The Yale Journal Of Biology And Medicine 2020, 93: 675-677. PMID: 33380928, PMCID: PMC7757055.Peer-Reviewed Original ResearchConceptsAtopic dermatitisRural-Urban Continuum CodesMedicare populationHealth Statistics Urban-Rural Classification SchemeInjectable biologicsSevere atopic dermatitisRetrospective cohort studyCohort studyPatient outcomesDupilumabFirst drugMedicare Provider UtilizationFDA approvalUtilization trendsFirst FDAFuture interventionsProvider UtilizationPotential targetBiologicsDisease treatmentPatientsTreatmentFirst yearMore rural regionsContinuum Codes
2011
The Role of Phenotyping in Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Mahal BA, Cohen JM, Allsop SA, Moore JB, Bhai SF, Inverso G, Dimitrakoff JD. The Role of Phenotyping in Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Current Urology Reports 2011, 12: 297-303. PMID: 21533747, DOI: 10.1007/s11934-011-0196-y.Peer-Reviewed Original ResearchConceptsChronic prostatitis/chronic pelvic pain syndromeChronic pelvic pain syndromeCP/CPPSPelvic pain syndromePain syndromeChronic pain syndromeCurrent symptom-based diagnosesSymptom-based diagnosisUnderlying biological mechanismsTreatment approachesClinical approachCurrent diagnosisSyndromeSuccessful managementDiagnosisTreatmentBiological mechanismsCPPSPainPathogenesisSymptomsMonths